Monopar Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Monopar Therapeutics Inc. (MNPR) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value of $40.50 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue · last filed 2026-08-12
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $40.50M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $16.50M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $3.60M; Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value as first filed $22.10M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $33.00M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value as first filed |
|---|---|---|
| 2026-06-30 | $40.50M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $16.50M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $3.60M 10-Q · filed 2026-05-14 | $22.10M 10-K · filed 2026-03-27 |
| 2025-09-30 | $33.00M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $8.00M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $8.40M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $3.40M 10-K · filed 2026-03-27 | $3.39M 10-K · filed 2025-03-31 |
| 2024-09-30 | $553.21K 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $223.54K 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $264.30K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $996.79K 10-K · filed 2025-03-31 | $131.41K 10-K · filed 2024-03-28 |
| 2023-09-30 | $200.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $300.00K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $500.00K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $917.80K 10-K · filed 2023-03-23 | |
| 2022-09-30 | $600.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $1.20M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $1.40M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $1.80M 10-K · filed 2022-03-24 | |
| 2021-09-30 | $2.70M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $3.30M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $3.60M 10-Q · filed 2021-05-13 | |
| 2020-09-30 | $3.00M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $4.90M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $4.60M 10-Q · filed 2020-05-07 | |
| 2019-09-30 | $3.30M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $3.30M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $3.30M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |